Clinical trials: Elderly Lymphoma Patients
MCL, Mantle Cell Lymphoma
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
This is a phase II trial, with the aim of developing a chemotherapy-free regimen for untreated patients with mantle cell lymphoma (MCL).
- Trial name
- ALTAMIRA (NCT05214183)
- Testing
- Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
- Where
- 20 sites in Denmark, Finland and 3 more
- Volunteers
- 81 people
- Sponsor
- Nordic Lymphoma Group
CLL, B-cell
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
This is a non interventional study to evaluate the efficacy and safety of Chlorambucil plus Rituximab as firstline therapy in elderly and/or unfit patients affected by B-cell Chronic Lymphocytic Leukemia (B-CLL).
- Conditions
- CLL, B-cell, Small Lymphocytic Lymphoma, Untreated B-CLL
- Trial name
- NCT01862445
- Where
- 20 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Elderly Lymphoma Patients
Evaluation of the Application of PEGylated Recombinant Human Granulocyte Stimulating Factor Injection (PEG-rhG-CSF) in Chemotherapy of Elderly Lymphoma Patients
A multicenter, open, one-arm clinical study evaluated the efficacy and safety of Jinyouli in preventing neutropenia after chemotherapy in elderly lymphoma patients who met the criteria for admission.
- Trial name
- NCT03870412
- Testing
- PEG-rhG-CSF
- Where
- China
- Volunteers
- 485 people
- Sponsor
- CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Diffuse Large B-Cell Lymphoma (DLBCL)
A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity.
- Trial name
- GOLD (NCT06828991)
- Testing
- Mosunetuzumab, ClonoSEQ
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Danielle Wallace
Lymphoma, Neurotoxicity
Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00666484
- Testing
- cyclophosphamide, doxorubicin hydrochloride, etoposide
- Where
- 5 sites in United Kingdom
- Volunteers
- 47 people
- Sponsor
- University College, London
Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib
Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL
This is a prospective, single-arm, phase II clinical study evaluating the efficacy and safety of Zanubrutinib (a BTK inhibitor) plus Lenalidomide (an immunomodulatory drug) in frail elderly patients with newly diagnosed primary…
- Conditions
- Primary Central Nervous System Lymphoma (PCNSL), Zanubrutinib, Lenalidomide, Frail Elderly
- Trial name
- NCT07839247
- Testing
- Zanubrutinib, Lenalidomide
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Xiaohui Ren
Lymphoma
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab and yttrium Y 90 ibritumomab tiuxetan can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00058422
- Testing
- darbepoetin alfa, filgrastim, rituximab
- Where
- 2 sites in United States
- Volunteers
- 65 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-cell Lymphoma
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease…
- Trial name
- NCT03677154
- Testing
- Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin
- Where
- 32 sites in United States, Israel and 4 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Lymphoma, Mantle-Cell
Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL
Prospective, multicenter, phase II trial designed to evaluate whether the addition of Venetoclax after rituximab, bendamustine and cytarabine (R-BAC) to high risk patients with mantle cell lymphoma improves the results of the…
- Trial name
- NCT03567876
- Testing
- Venetoclax
- Where
- 35 sites in Italy
- Volunteers
- 141 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
DLBCL - Diffuse Large B Cell Lymphoma
AZA Combined with R-GemOx for Elderly DLBCL Patients
This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of AZA（azacytidine）combined with the R-GemOx (rituximab, gemcitabine and oxaliplatin) regimen as first-line treatment in…
- Trial name
- Dragon (NCT06778902)
- Testing
- azacytidine, R-GemOx
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
GI Cancer, Lymphoma
Geriatric Communication Skills Training Program for Oncology Clinicians
The purpose of this study is to learn more about the effects of a training program designed to help doctors communicate better with older patients and their caregivers.
- Conditions
- GI Cancer, Lymphoma, GU Cancer, Bone Marrow Transplant
- Trial name
- NCT03530969
- Testing
- Self-Efficacy Assessment, UCLA Geriatrics Attitudes Scale, Course Evaluations
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Central Nervous System Neoplasms, Primary
Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma
This study will compare the overall survival (OS) time of elderly patients who would not tolerate standard chemotherapy for PCNSL treated with WBXRT together with Optune-TTF to those treated with whole-brain radiotherapy alone.
- Trial name
- NCT03530605
- Testing
- Optune TTF device
- Sponsor
- Saint Luke's Health System
Philadelphia Positive Acute Lymphoblastic Leukemia, Lymphoid Blastic Phase of Chronic Myeloid Leukemia
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)
The aims of the study are to determine whether single agent imatinib (STI571; Glivec) is more effective as up-front remission induction therapy than conventional multi-agent induction chemotherapy for elderly patients with…
- Trial name
- NCT00199186
- Testing
- imatinib, vincristine, cyclophosphamide
- Where
- Germany
- Sponsor
- Johann Wolfgang Goethe University Hospital
Mantle Cell Lymphoma (MCL)
Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years
This study is a prospective observational clinical trial. A total of 19 research centers were involved in this study. Each site plans to enroll 2-3 patients, and a total of 60 patients will be enrolled.
- Trial name
- NCT05406154
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Third Hospital
Follicular Lymphoma
Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma
This is a prospective, multicenter phase II trial designed to determine efficacy and safety of a brief chemoimmunotherapy with the combination of Rituximab + Bendamustine + Mitoxantrone in elderly patients with advanced stage…
- Trial name
- FLE09 (NCT01523860)
- Testing
- Rituximab, Mitoxantrone, Bendamustine
- Where
- 37 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
Brentuximab Vedotin in the Elderly Hodgkin Lymphoma Patients at First Relapse or With Primary Refractory Disease.
This is a single-arm, open-label, multicenter, clinical trial to evaluate the efficacy and safety of BV as a single agent in elderly patients at first relapse or with primary refractory HL.
- Trial name
- FIL_BVHD01 (NCT02227433)
- Testing
- Brentuximab Vedotin
- Where
- 6 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Chronic Lymphocytic Leukemia
Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project
FCR (fludarabine, cyclophosphamide, rituximab) combination is currently accepted as the gold standard in treatment of younger and physically fit CLL patients.
- Trial name
- Q-lite (NCT02156726)
- Testing
- low-dose FCR
- Where
- 7 sites in Czechia
- Volunteers
- 200 people
- Sponsor
- Czech CLL Study Group
Philadelphia Chromsome Positive Acute Lymphoblastic Leukemia
Evaluation of Efficacy and Safety of Nilotinib in Combination With Chemotherapy in Elderly Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The goal of this trial is to evaluate the efficacy and the tolerance of the combination of nilotinib with chemotherapy in the front-line setting as induction and consolidation therapy in Ph+ ALL patient aged 55 years and over.
- Trial name
- NCT01528085
- Testing
- Nilotinib
- Where
- 69 sites in France, Germany and 1 more
- Volunteers
- 79 people
- Sponsor
- Goethe University
Untreated T-cell Angioimmunoblastic Lymphoma
A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
To evaluate the efficacy and the safety of a front-line treatment combining CHOP regimen and rituximab in patients aged 60 to 80 years with previously untreated AIL.
- Trial name
- NCT00169156
- Testing
- Rituximab, Prednisone, Doxorubicine
- Where
- 4 sites in France
- Volunteers
- 27 people
- Sponsor
- Lymphoma Study Association
Lymphoma
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278408
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 152 sites in Denmark, Germany and 2 more
- Volunteers
- 700 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group